Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms

xlomafota13 shared this article with you from Inoreader Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms Via In vivo (Athens, Greece) In Vivo. 2021 Jul-Aug;35(4):2425-2432. doi: 10.21873/invivo.12520. ABSTRACT BACKGROUND/AIM: Little is known about the expression of L-type amino acid transporter 1 (LAT1) and 4F2hc in gastroenteropancreatic-neuroendocrine neoplasms (GEP-NENs). Hence, we conducted a study to verify the clinicopathological significance of LAT1 and 4F2hc. PATIENTS AND METHODS: Tissues from 126 patients with GEP-NENs were collected between August 2007 and September 2019 at our institution. We evaluated LAT1 and 4F2hc expression by immunohistochemistry, and examined their clinical significance. RESULTS: No statistically significant associations were observed between LAT1 expression and the different NENs. Expression of 4F2hc was significantly different between neuroendocrine tumour (NET)-G1, NET-G2, and NET-G3 (p=0.029), and was significantly associated with vascular invasion (p=0.044) and the Ki-67 index (p=0.042). CONCLUSION: No associat ion between LAT1 expression and malignant features in GEP-NENs was observed. However, an association between 4F2hc expression and the potential of malignancy in GEP-NENs was evident. PMID:34182526 | DOI:10.21873/invivo.12520 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.